Sun Nelson

CFO Sun Nelson buys 3,000 shares (3.0K) of AARD at $14.40; stock up 34.5% in 30 days but -17.1% from 52-week high

CFO Sun Nelson purchased 3,000 shares at $14.40 on 2025-12-11, increasing his holdings to 108,484 shares. The purchase occurs amid a +34.5% 30-day rally, though the stock remains -17.1% below its 52-week high. His prior trades at AARD show split outcomes: a September 2025 buy returned +105.5% over 90 days (well-timed), while a February 2025 buy returned -43.2% over the same window (poorly-timed), indicating inconsistent timing precision at this specific ticker. The company reported $0.00 in latest-quarter revenue and a $-16.3M net loss, placing this purchase in a pre-revenue biotech environment where fundamentals are immature. The timing—following a sharp 30-day recovery and mid-range relative to the 52-week band—lacks clear pattern alignment with his historical success rate on AARD.

CFO Sun Nelson buys 6,000 AARD shares at $8.07; stock down -53.6% from 52-week high, CFO's prior buy at this ticker delivered -43.2% 90d return.

Sun Nelson, the CFO, purchased 6,000 shares of Aardvark Therapeutics at $8.07 on 2025-09-09, increasing his holdings to 105,484 shares. The stock is trading at $8.00 (current price), down -53.6% from its 52-week high of $17.25 and down -28.2% over the prior 30 days. Notably, Nelson's own prior buy at AARD on 2025-02-14 resulted in a -43.2% return over 90 days, and his cross-ticker track record shows 1 prior open-market buy with an average 90-day return of -43.2% and a 0.00% win rate. The company is pre-revenue ($0.00 in the latest quarter) with a net loss of $-14,367,000.00 and a market cap of $173,575,144.00. The CFO's purchase at depressed valuation relative to historical price, combined with the company's lack of revenue and his prior unsuccessful buy at this same ticker, presents a pattern investors should monitor closely.

CFO Sun Nelson buys 10,000 shares of AARD at $16.00 for $160,000.00; 3 other insiders buying within 14 days

Sun Nelson, Chief Financial Officer of Aardvark Therapeutics, purchased 10,000 shares at $16.00 on 2025-02-14, bringing his holdings to 99,484 shares and representing an 11.2% increase in his pre-transaction position. The transaction occurs within a cluster pattern: 3 other insiders have also bought within the past 14 days, suggesting coordinated or simultaneous confidence at the same price level by multiple executives. The stock is trading at $14.90 as of 2025-02-19 (4 trading days post-transaction), reflecting a 6.9% decline from the CFO's execution price, though 52-week metrics are not yet meaningful given the recent listing. This is a derivative-conversion transaction with derivative holdings noted in Form 4 Table II; the reported Table I position does not represent the insider's full holdings. The cluster buying pattern by multiple executives warrants investor attention as a signal of near-term insider positioning.